Incomplete consent for psychotropic medications
Summary
The facility failed to ensure residents receiving psychotropic medications were educated on the risks and benefits of those medications and failed to obtain informed consent from the resident and/or representative before use. This affected three residents reviewed for unnecessary medications out of a sample of five, in a facility census of 45. The deficiency was identified through record review, staff interview, and policy review. Resident #32 was admitted with diagnoses including diabetes mellitus, rhabdomyolysis, dementia, anxiety disorder, and schizophrenia. The admission MDS dated 04/13/26 showed intact cognition, need for staff assistance with activities of daily living, and receipt of an anxiety medication, an antidepressant, and an antipsychotic. Physician orders included alprazolam 0.5 mg four times daily for anxiety, lurasidone 120 mg daily for schizophrenia, and sertraline 5 mg daily for depression, and the June 2026 MAR showed these medications were administered. The resident’s Psychoactive Medication Authorization dated 10/21/25 did not include or indicate the psychoactive medication or related diagnoses, and the DON confirmed this omission. Resident #42 had diagnoses including anxiety disorder, malignant neoplasm of the left breast, depression, dementia, and bipolar II disorder. The quarterly MDS dated 05/04/26 showed intact cognition, need for staff assistance with activities of daily living, and receipt of an antipsychotic medication. Orders included lorazepam 0.5 mg daily for anxiety and risperidone 0.5 mg and 1 mg twice daily for bipolar disorder, and the June 2026 MAR showed these medications were given. The Psychoactive Medication Authorization dated 08/26/25 did not identify the psychoactive medication or related diagnosis, and the DON confirmed the consent forms failed to indicate the medication being administered and the diagnosis for use. Resident #4 was admitted on 10/16/25 with diagnoses including non-ST elevation myocardial infarction, displaced intertrochanteric fracture of the femur, chest pain, atherosclerotic heart disease, hyperlipidemia, hypertension, cerebrovascular disease, and paranoid schizophrenia. The quarterly MDS submitted 05/18/26 showed a BIMS score of 12, verbal behavioral symptoms, self-injurious behaviors, daily rejection of care, and daily use of antipsychotic medications. The record included an order for fluphenazine decanoate 2.5 mg/mL intramuscularly monthly for schizophrenia. The Psychoactive Medication Authorization form dated 10/24/25 did not identify the medication, did not list side effects, and had a signature line marked only as verbal without naming the person who gave consent; the DON confirmed the authorization was incomplete.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release October 8, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.